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Abstract
New oral anticoagulants to reduce the incidence of thrombosis have recently become available.
When compared to the existing therapy, warfarin, these novel agents have similar efficacy with a
reduced risk of spontaneous bleeding. However, these novel agents have been associated with
significant, even fatal, bleeding following trauma. Reversal agents are being developed that bind
and neutralize these oral anticoagulants. However, these are not yet available. Another strategy is
to increase thrombin generation by administration of “bypassing” agents such as prothrombin
complex concentrates or factor VIIa. Several animal models have been used to model the
hemostatic defect induced by the thrombin inhibitor dabigatran. A rat tail injury model, a rabbit
cuticle bleeding model, and a rabbit kidney laceration model have all been reported to show
increased bleeding, but with supratherapeutic doses of dabigatran. A mouse tail transection model
has been reported to reflect increased bleeding at peak therapeutic dabigatran levels. We found
that the Whinna saphenous vein hemostasis model reliably reflects a hemostatic defect at
therapeutic levels of dabigatran. This model can potentially reflect the effects of reversal or
bypassing agents.
Introduction
Thrombosis represents a serious health problem in the US and Europe with more than 1% of
the population currently taking medication to reduce the risk of thrombosis. The new oral
anticoagulants (dabigatran that targets thrombin and rivaroxaban or apixaban that target
factor Xa) have been shown in clinical trials to have good efficacy in preventing thrombosis
with a reduced risk of spontaneous bleeding relative to warfarin [1,2]. In particular, fatal
bleeds and intracranial hemorrhage were reduced relative to warfarin. Despite the lower risk
of spontaneous bleeding, in trauma these oral anticoagulants have been associated with
significant bleeding leading to serious adverse events [3,4].
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This trauma induced bleeding has led to a search for agents to reverse the effects of the oral
anticoagulants. Reversal agents that bind the thrombin and factor Xa inhibitors, effectively
removing them from circulation, are being developed [5–7]. Since these reversal agents have
not yet been approved, one strategy has been to use factor VIIa and prothrombin complex
concentrates in patients presenting with trauma while on oral anticoagulants [8,9]. While not
direct neutralizers of the anticoagulants, factor VIIa and prothrombin complex concentrates
act as “bypassing” agents to boost factor Xa and thrombin generation sufficiently to stabilize
the patients through surgery.
In this context, it would be valuable to have a model to assess in vivo bleeding due to these
oral anticoagulants. Such a model could be a tool to assess bypassing and reversal agents.
We have previously described a Saphenous vein injury model that has been used to examine
bleeding in mice with hemophilia and to assess therapy in those mice [10,11]. We
hypothesized that this model might be useful to examine the effects of the novel
anticoagulants on hemostasis.
Materials and Methods
Dabigatran (BIBR 953) was purchased from (Selleck, Houston, TX). The dabigatran
concentration was determined by adding a high concentration of thrombin (30 nM) to varied
dabigatran (0-100 nM). Residual thrombin was detected with a substrate that binds poorly to
thrombin (Pefachrome FXa; Pentapharm, Basel, Switzerland). Dabigatran concentration was
determined from the intercept of the plot of residual activity vs concentration of dabigatran
assuming a one to one molar interaction with thrombin.
All animal protocols were approved by the Institutional Animal Care and Use Committee of
the University of North Carolina. C57BL6/J mice were purchased from Charles Rivers
Laboratories (Willmington, MA). Bleeding studies were done essentially as previously
described [10,11]. Mice were anesthatized with isoflurane throughout all procedures. The
hair on the ventral side of both hind limbs was removed. The animals were placed supine on
a temperature and ECG monitoring board. The paws were gently restrained by looping soft
polyethylene tubing around them and attaching attaching the tubing to the ECG board. The
skin on the left and right ventral hind limb was incised which exposes a length of the
saphenous neurovascular bundle; the bundle was covered with normal saline to prevent
drying. To allow for injection of dabigatran, the left saphenous vein was cannulated. To
assess hemostasis, the right saphenous vein was transected by piercing it with a 23-G needle
followed by a longitudinal incision made in the distal portion of the vessel. Blood was
gently wicked away until hemostasis occurred. The clot was then removed to restart
bleeding and the blood was again wicked away until hemostasis occurs again. Clot
disruption was repeated after every incidence of hemostasis for 30 minutes. Two parameters
were measured: 1) the number of times that hemostasis occurs in a 30 minute period, and 2)
the time required for each hemostasis. At the conclusion of hemostasis measurements, blood
was withdrawn from the inferior vena cava; 9 parts blood were mixed with 1 part 0.109 M
citrate.
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Administration of 15 μg/kg dabigatran intravenously produced plasma levels of about 65
ng/mL. Dabigatran levels were assessed using a thrombin time assay in which one part
mouse plasma as the source of dabigatran was mixed with one part normal pooled human
plasma as a standardized source of fibrinogen. Clotting was initiated by addition of one part
plasma to one part 1 NIH U/mL thrombin (without addition of calcium). Clotting times were
converted to dabigatran concentration from a standard curve generated using known
concentrations of the inhibitor.
Comparison of treated to untreated animals was done by a two sided Student's t-Test
assuming equal variance in the samples.
Results
The hemostasis times for an individual mouse were averaged to obtain a single value for
each mouse. Wild type mice (n=8) have an average hemostasis time of 86 seconds (+/- 18
seconds) as shown in Figure 1A. This same data can be expressed as the number of
disruptions within a thirty minute period. In this study wild type mice had 19.2 (+/- 3.2)
disruptions (FIgure 1B). When wild type mice were injected with 15 μg/kg dabigatran
(n=11), they had plasma levels of 63 (+/- 18) ng/mL at the conclusion of the bleeding
studies. These animals had their average hemostasis time prolonged to 171 (+/−33) seconds
and had only 9.7 (+/- 1.7) disruptions; both were significantly different from wild type
(p<0.001).
Conclusions
The Whinna saphenous vein hemostasis model was initially developed to assess bleeding in
hemophilia [10,11]. One of the features of this model is that it is sensitive to relatively low
doses of hemostatic agents; in studies on recombinant factor VIII, average hemostasis time
was virtually corrected by administration of only 10 U/kg factor VIII [11]. By contrast, the
commonly used model of tail vein transection is a much more significant injury and,
unsurprisingly, in hemophilia A mice doses of up to 100 U/kg factor VIII were required to
normalize blood loss in >80% of the animals [12].
In preclinical animal studies on the efficacy and safety of dabigatran, one of the initial
observations was that the dose required to cause bleeding was much higher than the dose of
dabigatran that prevented thrombosis. Wienen et al showed using rats that in a Wessler
model of the inferior vena cava, venous thrombus weight could be dose dependently reduced
by bolus administration of dabigatran [13]. The ED50 for this reduction of thrombus weight
was 33 μg/kg. By contrast, in a model that used a spring loaded device to create a
standardized injury on a rat tail, up to 300 μg/kg dabigatran did not show bleeding [13]. This
result was consistent with another study that looked at a rabbit cuticle bleeding time as a
measure of hemostasis [14]. In the rabbit study, bleeding was only observed at high plasma
levels of dabigatran (ED50 of 500 ng/mL (1079 nM)).
In order to study the role of bypassing agents in reversing bleeding, a model of a
standardized kidney injury was used [15]. In this model, a defined (15-mm long and 5mm
deep) scalpel incision was made at the lateral kidney pole of a rabbit. The time required for
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this injury to stop bleeding was measured (30 min max). In this study, rabbits were
administered 400 μg/kg dose leading to peak dabigatran levels of 800 ng/mL. These are
levels that would be expected only in patients after overdose or with impaired clearance due
to renal failure. Another study to look at reversal of bleeding used a tail transection model in
mice [16]. Mice were given dabigatran etexilate by oral gavage; this resulted in a dose
dependent increase in blood loss from 6 minutes in untreated animals to 13 minutes in
treated animals. For the reversal study, levels of 200 ng/mL were used. This dabigatran level
is similar to peak levels seen in patients taking 300 mg once a day.
In the studies presented here, dabigatran treatment prolonged the average hemostasis times;
the dabigatran levels in these mice (63 +/- 18 ng/mL) fall between the peak (89 ng/mL) and
trough levels (14 ng/mL) seen in patients taking 150 mg dabigatran etexilate once daily [17]
and are close to the steady state trough levels seen in patients who are taking 110 mg
dabigatran etexilate twice daily [18]. So in this model, hemostasis is prolonged at dabigatran
concentrations within the range of normal therapeutic levels. This study is limited since only
a single dose of dabigatran was studied. It is not clear if higher plasma levels of dabigatran
would result in more significant bleeding although, by analogy to the tail transection study
where there was a dose dependent increase in bleeding [16], we expect the bleeding in this
model to show dose dependence.
In summary we have established that a saphenous vein hemostasis model can assess
bleeding in mice that have levels of dabigatran comparable to therapeutic levels in patients.
Preliminary data shows that this model is useful for testing the in vivo efficacy of bypassing
agents [19] and may be useful for testing the efficacy of reversal agents.
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Effect of dabigatran on a saphenous vein bleeding model. A. Bleeding over 30 minutes was
measured by disruption of hemostatic clots as described in Methods. Average hemostasis
times for wild type C57BL6/J mice (n=8) and C57BL6/J mice injected with 15 μg/kg
dabigatran (n=11) are plotted; each dot represents an animal. The mean and standard
deviation are shown. Wild type differs from dabigatran treated (p<0.001). B. The data in
Figure 1A can be expressed as the number of disruptions in 30 minutes; the error bar shows
the standard deviation. Wild type differs from dabigatran treated (p<0.001).
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